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Abstract A novel protein family, showing a conserved proregion 
and a variable C-terminal antimicrobial domain, and named 
cathelieidin, has been identified in mammalian myeloid cells. The 
conserved proregion shows sequence similarity to members of the 
cystatin snperfamily of cysteine proteinase inhibitors. Cathelicid- 
ins are stored in the cytoplasmic granules of neutrophil eukocytes 
and release the antimicrobial peptides upon leukocyte activation. 
Some of these peptides can assume an a-helical conformation, 
others contain one or two disulfide bonds, still others are Pro- and 
Arg-rich, or Trp-rich. In addition to bacterial killing, some of 
these peptides exert additional functions related to host defense 
such as LPS-neutralization and promotion of wound healing. 
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1. Introduction 
A rapid and effective response to challenge by pathogens i
essential for the survival of all living organisms. Among the 
several different defense mechanisms which have evolved to 
meet his necessity is the production of a large variety of micro- 
bicidal peptides; over 100 have been isolated so far from both 
animals and plants [1,2]. These peptides play a major role in the 
immune defense of invertebrates, while in vertebrates they act 
as a first line of defense against invasion by pathogens and in 
the control of the natural flora [2,3]. The importance of these 
peptides can be inferred from their specific localization at sites 
which are exposed to microbial invasion as well as in the profes- 
sional phagocytes. They are in fact produced in the epithelia of 
amphibia [3], mammals [4-6] and insects [2,7], are secreted into 
internal body fluids in arthropodes [2,7] and are stored in the 
cytoplasmic granules of professional phagocytes of mammals 
and birds [8-11]. 
Based on the presence or absence of disulfide bonds, these 
peptides can be divided into two broad classes, each including 
several peptide families (Table 1). Among the most studied 
families are those comprising linear peptides like the insect 
cecropins [2,7], amphibian magainins [3] and Pro- and Arg-rich 
peptides from mammals [12,13]. Defensins are another well 
studied family of mammalian myeloid and epithelial peptides, 
characterized by the presence of three disulfide bridges that 
maintain the molecule in a compact,B-sheet structure [5,10]. In 
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spite of the significant diversity of sequence and structure in the 
different peptide families, some common features appear to be 
required for their activity, such as a high content of basic 
residues and the tendency to adopt an amphipathic conforma- 
tion, which accounts for their functioning as membrane-disrup- 
tive agents. 
The spectrum of organisms usceptible to these peptides is 
broad [2-11], including various bacteria, protozoa, fungi, and 
in some cases, virally infected and tumor cells. Their antimicro- 
bial and cytotoxic effects are mediated by the ability to bind and 
permeabilize the surface membrane of the target cells 
[2,4,7,10,14]. The initial binding is thought o depend on elec- 
trostatic interactions between the positively charged residues of 
the peptides and the negatively charged molecules exposed at 
the target cell surface. They may then float with their hydro- 
phobic face buried in the lipid bilayer [15], or form transmem- 
brane channels in a voltage-dependent manner [2,3,5,7,10]. 
These interactions lead to alteration of membrane permeability, 
with leakage of metabolites [10,14]. The preferential selectivity 
for prokaryotic and transformed eukaryotic ell membranes 
seems to depend on the different lipid composition of bacterial 
and transformed cell membranes with respect to normal eukar- 
yotic membranes [16,17]. 
Unlike most of the classical antibiotics, which are built in a 
stepwise manner through acomplex enzymatic synthesis, all the 
known antimicrobial peptides are made from gene-encoded 
precursors (prepropeptides), from which the mature peptides 
are derived by the sequential removal of the signal peptide and 
of a variably extended prosequence. In general the propiece 
precedes the mature peptide, is anionic and, at least in some 
cases, has been suggested to play a role in targeting and/or in 
assisting the correct folding of the antimicrobial peptide [18]. 
The preproregion is often highly conserved within families of 
antimicrobial peptides, as deduced from sequence analysis of 
the precursors at the cDNA level, thus suggesting that members 
of each family evolved from ancestor genes through duplication 
and modification. 
2. Cathelicidins, a novel family of antimicrobial peptide 
precursors 
A rapidly expanding roup of antimicrobial peptide precur- 
sors with unique features has recently been identified in myeloid 
cells. Precursors of this type have highly identical N-terminal 
preprosequences, followed by highly variable C-terminal se- 
quences which correspond to the antibacterial peptides (Fig. 1). 
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Table 1 
Structure-based classification of animal antimicrobial peptides 
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Peptides with disulfide bonds Peptides without disulfide bonds 
Peptides with three disulfide bonds: 
Defensins, cryptdins, mammals 
fl-defensins mammals, birds 
Insect defensins insects 
Peptides with two disulfide bonds: 
*Protegrins 
Tachyplesins, polyphemusins 
Peptides with one disulfide bond: 
*Cyclic dodecapeptide 
Brevinins, ranalexin, esculentin 
Mostly or-helical peptides: 
*PMAP-36 and -37, *CAP18, *FALL-39 mammals 
Magainins, dermaseptins amphibia 
Cecropins insects 
Pro- and Arg-rich peptides: 
mammals *Bactenecins, *PR-39, *prophenin mammals 
horse-shoe crabs Apidaecins, abaecin, drosocin insects 
mammals 
amphibia 
Trp-rich peptides: 
*Indolicidin, *PMAP-23 mammals 
Gly-rich peptides 
Hymenoptaecin, coleoptericin insects 
Representative peptides and peptide families are reported (see refs. in [2 5,7,10]). Peptides derived from cathelicidins are indicated by asterisks. 
The presence of a conserved 5' region in the mRNAs of these 
precursors allowed the amplification of the cDNAs of novel 
congeners. In these putative precursors the conserved domain 
is followed by previously unknown sequences with structural 
features consistent with antibacterial activity. These prepropep- 
tides have molecular masses of 16 26 kDa, and have been 
identified in bovine [19 22], porcine [23 29], rabbit [30,31] and, 
more recently, human [32,33] myeloid cells. The sequence is 
comprised in most cases of a highly conserved preproregion of 
128-143 residues including a putative 29-30 residue signal pep- 
tide and a propiece of 99-114 residues, and a C-terminal region 
ranging in length from 12 to 100 residues (Fig. 2). The mature 
peptides corresponding to the C-terminal sequences have all 
been given individual names that identify them as such. At 
present they include the bovine cyclic dodecapeptide [34], Bac5 
[35], Bac7 [35] and indolicidin [36]; the porcine PR-39 [13], 
PMAP-36 [26], PMAP-37 [29], PMAP-23 [27], protegrins [37] 
and prophenin [38]; rabbit CAP18(106-142) [39] and human 
FALL-39/CAP18 [32,33]. 
The prosequence which is present in the precursors of these 
peptides is highly identical to the sequence of a protein termed 
cathelin. This protein was isolated from porcine leukocytes [40], 
and is likely to be the proregion of a processed precursor of this 
type, from which the C-terminal antimicrobial peptide has been 
released (Fig. 1). Based on the presence of a common cathelin- 
like domain, we propose the name cathelicidins for this group 
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Fig. 1. Alignment of cathelicidin sequences (cathelin-like proregion and C-terminal antimicrobial domain), as deduced from porcine (P) [23-29], 
human (H) [32,33], bovine (B) [19 22] and rabbit (R) [30,31] myeloid cDNAs. The sequence of the PMAP-37 proregion is in black capital letters. 
Red dashes denote identical residues in other congeners. C- terminal antimicrobial domains are in blue, while amidation signals are in red. Gaps 
are indicated by dots. The amino acid sequence of cathelin was determined by Edman degradation [40]. 
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Fig. 2. Schematic representation f prepropeptides of the cathelicidin 
family. 
of precursors, and this term will be used herewith to indicate 
molecules with a cathelin-like proregion and a C-terminal an- 
timicrobial domain. 
Several mismatches in the 5' regions indicate that, in general, 
cathelicidins do not originate by posttranscriptional process- 
ing. The genes for one porcine [2] and one bovine (Scocchi, M. 
et al., unpublished) precursor have been sequenced and both 
have been shown to contain four exons. The preproregions 
share a high similarity, with an intra-species identity of 90-97% 
for porcine, and 75 87% for bovine preprosequences. The rab- 
bit congeners show the lowest degree of similarity. In particu- 
lar, rabbit p15 is the only congener which is not processed to 
give a free C-terminal peptide [31]. Four invariant cysteines 
clustered in the C-terminal region of the cathelin-like propiece 
are arranged to form two intramolecular disulfide bonds 
(Storici, E et al., unpublished), which may impose structural 
constraints on the molecule. When the prosequence is com- 
pared with other known proteins, the best alignment scores are 
with members of the cathelicidin family, immediately followed 
by members of the cystatin superfamily, proteins known to 
inhibit cysteine proteinases [41]. The most significant align- 
ments are with the cystatin-like domains of kininogens. For 
instance, a stretch of 92 residues of the propiece of bovine Bac5 
(residues 36-127 of preproBac5 in ref. [21]) shows a 22% iden- 
tity and a further 37% similarity with the third cystatin-like 
domain (residues 277-370) of bovine kininogen II [42], includ- 
ing alignment of all four cysteines comprised in this segment. 
This sequence may thus be considered a modular unit associ- 
ated to a number of different and rapidly evolving C-terminal 
domains. 
Cathelicidins are expressed early in myeloid differentiation, 
and their mRNAs are not detectable in mature neutrophils. 
Human FALL-39 mRNA is also expressed in testis [32], and 
PR-39 has been isolated from pig intestine [13], suggesting that 
the peptides derived from these precursors might contribute to 
the control of microbial growth also in these anatomic om- 
partments. Studies on the biosynthesis and the intracellular 
processing of the precursors of Bac5 and Bac7, the most exten- 
sively characterized antimicrobial peptides of this group, indi- 
cate that they are synthesized in bone marrow myeloid cells as 
prepropeptides. These are processed by the removal of the 
signal peptide to proforms which are stored in the large gran- 
ules of bovine neutrophils [43]. Western analysis of bovine and 
porcine neutrophils, using specific antibodies, has shown that 
other members of this family are also stored as proforms and 
some have been purified from bovine neutrophils (Storici, P. et 
al., unpublished). 
As shown for proBac5 and proBac7, cathelicidins can be 
released extracellularly from granules by neutrophil stimulants 
[44]. Purified proBac5 and proBac7 do not display antimicro- 
bial activity [45], most likely because the anionic propiece 
causes inactivation of the cationic C-terminal peptide. ProBac5 
has been shown to inhibit the in vitro activity of the cysteine 
proteinase cathepsin L [46], which provides additional evidence 
for the evolutionary relatedness of the prosequence with the 
cystatin superfamily of cysteine proteinase inhibitors. This in- 
hibitory effect is exerted with a Ki value of 60 nM, which is 
some orders of magnitude higher than those of cystatins (K~ 
values of 0.23 nM and 0.005 nM for human cystatin B and C, 
respectively) and kininogens (K~ of 0.017 nM for human L- 
kininogen) [47]. Whether this trace of a common evolutionary 
origin also has functional implications inmodulating inflamma- 
tory responses i not yet clear, and further structural and func- 
tional studies are needed in order to assess its physiological 
significance. 
Investigations on possible function(s) of the conserved N- 
terminal domain may help unravel important aspects of the 
biology of cathelicidins. Indeed, the evolutionary pressure x- 
erted towards conservation of this prosequence suggests it may 
have a role in specific functions uch as targeting of the anti- 
microbial peptides to the granules or aiding their correct prote- 
olytic maturation. Studies on the maturation of the bovine 
Pro- and Arg-rich peptides have shown that the N-terminal 
conserved region is cleaved off by elastase under conditions 
that favour concomitant release of the contents of the large 
granules and the azurophils (i.e. granule discharge into 
phagocytic vacuoles) [44,45]. This enzyme liberates the mature 
antimicrobial peptide at a specific valyl residue of the precur- 
sor. Most cathelicidins have cleavage sites for elastase at corre- 
sponding positions and may undergo a similar processing. 
3. Structure and function of the mature C-terminal peptides 
The C-terminal sequences are structurally varied (Fig. 1) and 
in several cases [19,21,23 26,28] show a C-terminal amidation 
Table 2 
Antibacterial ctivity of peptides corresponding to the active C-terminal domain of cathelicidins 
Organism Minimal inhibitory concentration (pM) 
Bac5 Bac7 PMAP-36 (1 20) PMAP-37 PMAP-23 CAPI8 (10(~125) 
E. coli 2 2 12 1 4 4 
S. typhirnurium 2 2 48 4 8 2 
P. aeruginosa >40 8 3 2 16 0.5 
S. aureus >40 >40 6 32 4 4 
B. megaterium 2 2 3 4 2 4 
The minimal inhibitory concentration (MIC) is defined as the lowest peptide concentration preventing visible growth of approximately 1.5 x 105 colony 
forming units/ml after 18 h incubation at 37°C [35]. Results have been obtained by using natural Bac5 and Bac7 [35] and synthetic PMAP-36(1-20) 
[26], PMAP-37 [29], PMAP-23 [27] and CAP18(106-125) [51]. 
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signal. Peptides corresponding to all known sequences have 
either been purified from natural sources [13,34-39], after proc- 
essing of the respective precursors, or have been obtained by 
chemical synthesis based on the sequence deduced from cDNA 
[26,27,29,32,33]. At present hey include rabbit CAPI8(106 
142) [39], human FALL-39/CAP18 [32,33], PMAP-36 [26] and 
PMAP-37 [29], all of which are mostly s-helical; two Trp- 
containing peptides, indolicidin [36] and PMAP-23 [27]; the 
Pro- and Arg-rich Bac5 [12], Bac7 [12], PR-39 [13] and pro- 
phenin [38]; the cyclic dodecapeptide [34] and protegrins [37] 
which are loop-forming molecules with one and two disulfide 
bonds, respectively. The sequence of the Pro- and Arg-rich 
peptides (Fig. 1) is peculiar in that several short modules are 
present, and often arranged in tandem repeats [12,13,38]. 
The structure of some of these peptides has been analyzed 
by circular dichroism spectroscopy, showing that PMAP-36 
[26], PMAP-37 [29] and FALL-39 [32] undergo a transition 
from a random coil to an ordered, mainly s-helical conforma- 
tion on addition of an organic solvent. This behaviour indicates 
the presence of an amphipathic s-helical conformation, a struc- 
ture found in many membrane-active p ptides. A polyproline 
type structure has been suggested for PR-39 [48] and, based on 
sequence similarity, such a structure might also occur in Bac5 
and Bac7, although this still requires confirmation. 
Peptides derived from cathelicidins exert a broad spectrum 
antibacterial ctivity at ,umolar concentrations, with a wide 
overlap in specificity but also with significant differences in 
potency among each other (Table 2). The Pro- and Arg-rich 
peptides are substantially more active against gram-negative 
than gram-positive bacteria [13,35,38]. Conversely, the other 
linear (helical and Trp-rich) and Cys-containing peptides are in 
general highly active against both gram-positive and gram- 
negative microorganisms [26,27,32,34,36,37,49]. Protegrins also 
exhibit fungicidal activity [37], while Bac5 and Bac7 kill lepto- 
spirae [50]. 
Although several approches have been used to investigate he 
mode of action of these peptides, our understanding of their 
killing mechanism(s) is still incomplete. Many of them have 
been shown to rapidly permeabilize the membranes of suscepti- 
ble bacteria [14,26,27,29,51]. The Pro- and Arg-rich Bac5 and 
Bac7 inhibit incorporation of precursor molecules into protein 
and RNA [14] and PR-39 has been shown to stop protein and 
DNA synthesis in gram-negative bacteria [52]. 
In addition to antimicrobial ctivity, some of these peptides 
display other functions. Rabbit and human CAP18 bind LPS, 
inhibit multiple LPS biological activities in vitro, and reduce 
LPS lethality in murine models of endotoxemia [33,53], whereas 
PR-39 can induce expression of cell surface heparan sulphate 
proteoglycans (syndecan-1 and -4), as part of the wound repair 
process [54]. These molecules thus appear to be capable of 
performing several functions, such as bacterial killing, LPS- 
neutralization, inhibition of a tissue-degrading enzyme and 
promotion of wound healing, which in general are related to 
the protection of the host. 
4. Conclusions 
The cathelicidin family was first recognized in 1993 [21] and 
now counts numerous members (Fig. I) which are distributed 
among various mammalian species. Most of these congeners 
have been identified through molecular biological approaches 
that are based on the high conservation of their prosequence. 
These effector molecules of innate immunity are peculiar in that 
a highly conserved proregion is associated to a highly variable 
and biologically active unit. An analogous case may be that of 
the mouse antimicrobial cryptdin mRNAs, which show pre- 
proregions imilar to those of other Cys-rich sequences whose 
function, however, is as yet unknown [55]. The functional or- 
ganization of cathelicidins in constant and variable regions in 
a sense parallels that used in antigen-driven immunity, albeit 
at a much lower level of complexity. 
A number of studies have led to a relatively good character- 
ization of the antibacterial domains, whereas the several puta- 
tive roles that have been proposed for the conserved proregion 
remain to be verified. Furthermore, the structural organization 
of cathelicidins poses interesting questions concerning the ge- 
netic mechanisms by which they have been generated. Some 
indications have come from cDNA sequence analysis of the 
protegrin gene which appears to have arisen from insertion of 
a protegrin coding region into a pre-existing C12/prophenin 
gene [28]. Similar insertional events may have generated bovine 
Bac7 and porcine PR-39 from a common ancestor gene [22]. 
However, these mechanisms cannot fully explain the high diver- 
sity shown by this family. Thus, research in the future should 
also aim at obtaining a better knowledge of the various mech- 
anisms which worked at the genomic level to produce this 
component of innate immunity. 
5. Note added in proof 
After the submission of this manuscript, the structure of 
the genes coding for the porcine cathelicidins PR-39 
(Gudmundsson, G.H., Magnusson, K.P., Chowdhary, B.E, 
Johansson, M., Andersson, L. and Boman, H.G. (1995) Proc. 
Natl. Acad. Sci. USA 92, 7085 7089) and protegrins (Zhao, C., 
Ganz, T. and Lehrer, R.I. (1995) FEBS Lett. 368, 197-202) 
were reported. 
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